US5354682A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Viral-safe purified human thrombin
Assignee: Baxter International Inc
•
Filing: 1993-02-24
•
Granted: 1994-10-11
•
Expires: 2013-02-24
Abstract
Abstract A purified therapeutic grade thrombin is described which is essentially free of lipid envelope viruses, has a specific activity of about 2200 NIH units per milligram of protein to about 3200 NIH units per milligram of protein, is essentially homogeneous and may be produced on a commercial-scale. The thrombin is acceptable from human administration.
Inventors
- 👤 Henry S. Kingdon
- 👤 Michael J. Griffith
- 👤 Joyce Lawrence
- 👤 Roger L. Lundblad
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 05:38
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/6429; A; A61; A61L; A61L2/00; A61L2/16; A61P; A61P7/00; A61P7/04; C12Y; C12Y304/00; C12Y304/21; C12Y304/21005; A61K; A61K38/00; A61L2103/00; A61L2103/05; A61L2103/09
Claims Analysis
Total Claims: 2
Claim 1
Independent Claim
116 words
A therapeutic grade thrombin, said thrombin, a) being essentially homogeneous when analyzed by SDS polyacrylamide gel electrophoreses, C 3 -HPLC chromatography, and immunodiffusion; b) having a total nucleic acid content of less than 10 pg per therapeutic dose; c) being contaminated by blood coagulation Factors VII, IX and X of less than 1 percent by weight in the aggregate; d) having a level of inactivated prothrombin of less than 0.1 percent; e) having a level of inactive prothrombin fragments of less than 5.0 percent; f) having a specific activity ranging minimally from about 2200 NIH units per mg protein to about 3200 NIH units per mg protein; and, g) being essentially free of lipid envelope viruses.
Claim 2
Dependent Claim
116 words
A therapeutic grade thrombin, said thrombin, a) being essentially homogeneous when analyzed by SDS polyacrylamide gel electrophoreses, C 3 -HPLC chromatography, and immunodiffusion; b) having a total nucleic acid content of less than 10 pg per therapeutic dose; c) being contaminated by blood coagulation Factors VII, IX and X of less than 1 percent by weight in the aggregate; d) having a level of inactivated prothrombin of less than 0.1 percent; e) having a level of inactive prothrombin fragments of less than 5.0 percent; f) having a specific activity ranging minimally from about 2200 NIH units per mg protein to about 3200 NIH units per mg protein; and, g) being essentially free of lipid envelope viruses.
References Cited (Backward Citations)
US2495298A
Cited
US4170590A
Cited
US4137127A
Cited
US4315919A
Cited
US4380511A
Cited
US4774076A
Cited
US4960702A
Cited
SU1527261A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-10-10 | 1998-04-11 | 1998-10-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-10-10 | 2002-04-11 | 2002-10-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-10-10 | 2006-04-11 | 2006-10-11 | $7700.00 | Window Closed / Lapsed |